Assembly biosciences reports positive interim phase 1a results from clinical trial evaluating long-acting helicase-primase inhibitor abi-1179 in development for recurrent genital herpes

– abi-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose –
ASMB Ratings Summary
ASMB Quant Ranking